Premium
Pharmacokinetics of phenytoin and its metabolite, 4′‐HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin
Author(s) -
Kim Yu C.,
Kang Hee E.,
Lee Myung G.
Publication year - 2008
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.591
Subject(s) - phenytoin , medicine , pharmacokinetics , oral administration , streptozotocin , diabetes mellitus , endocrinology , alloxan , metabolite , pharmacology , epilepsy , psychiatry
It has been reported that diabetic patients have an increased risk of developing epileptic convulsions compared with the non‐diabetic population, and phenytoin has widely been used for neuralgia in diabetic neuropathy. It has also been reported that in both diabetic rats induced by alloxan (DMIA rats) and by streptozotocin (DMIS rats), the protein expression and mRNA level of 2C11 decreased, but in DMIS rats, the protein expression of CYP2C6 increased. Thus, the pharmacokinetics of phenytoin and 4′‐HPPH were investigated after intravenous or oral administration of phenytoin at a dose of 25 mg/kg to DMIA and DMIS rats. After intravenous or oral administration of phenytoin, the AUC (or AUC 0–12 h ) values of both phenytoin and 4′‐HPPH were comparable (not significantly different) between each diabetic and the respective control rats. Although the exact reason is not clear, this could have been due to opposite protein expression (and/or mRNA levels) of CYP2C6 and 2C11 in diabetic rats. Copyright © 2007 John Wiley & Sons, Ltd.